Circular Genomics Launches Blood Test Platform for Early Alzheimer's Detection

What Happened

Circular Genomics on July 1, 2026, announced the commercial launch of its CircPATH platform, a blood-based diagnostic tool designed to detect Alzheimer's disease in preclinical stages, before patients show any symptoms. The announcement followed the publication of a landmark study in Nature Medicine that the company says validated the platform's performance against existing gold-standard diagnostic tests.

The Technology

CircPATH uses circular RNA biomarkers found in blood samples to identify biological signals associated with Alzheimer's disease. According to the company's announcement, the platform outperformed gold-standard diagnostic tests in the Nature Medicine study and demonstrated the ability to stratify patients by risk years before symptom onset.

Circular RNA is a form of ribonucleic acid that, unlike linear RNA, forms a closed loop structure. Circular Genomics has built its diagnostic approach around detecting specific circular RNA signatures in blood rather than relying on more invasive or expensive procedures such as cerebrospinal fluid analysis or PET imaging, which are currently used in clinical settings for Alzheimer's biomarker testing.

Study Findings

The Nature Medicine publication, which served as the scientific basis for the platform launch, reported that CircPATH blood-based markers outperformed existing gold-standard tests in detecting preclinical Alzheimer's risk. The company states the platform enables risk stratification at a stage of disease progression that current standard-of-care tools do not routinely reach.

The company did not disclose in its announcement the specific sensitivity and specificity figures from the study, nor the size of the patient cohort used in the research. Those details are available in the Nature Medicine publication.

Company Background

Circular Genomics is a biotechnology company focused on circular RNA biology as a basis for diagnostic and therapeutic applications. The CircPATH launch represents the company's first commercial platform offering. The company has not previously made major public announcements regarding regulatory submissions or commercial partnerships, based on available wire reporting.

Regulatory and Market Context

Alzheimer's disease affects an estimated 55 million people worldwide, according to the World Health Organization. Early detection has been a persistent clinical challenge, as symptoms typically emerge only after significant neurological damage has already occurred. Blood-based biomarker testing for Alzheimer's has been an active area of research and regulatory activity. The U.S. Food and Drug Administration cleared the first blood-based Alzheimer's biomarker test for clinical use in 2024, establishing a regulatory pathway that subsequent platforms are expected to follow.

Circular Genomics did not specify in its announcement whether CircPATH has received FDA clearance or approval, or whether the company has submitted the platform for regulatory review. The announcement described the launch of the platform following the Nature Medicine study, without providing detail on the regulatory status of the product for clinical diagnostic use in the United States.

What It Means in Practice

If validated at scale and cleared by regulators, a blood-based test capable of detecting Alzheimer's risk years before symptom onset could reduce reliance on PET scans and lumbar punctures, both of which carry higher costs and greater procedural burden for patients. Preclinical risk stratification could also expand eligibility assessment for clinical trials of disease-modifying therapies, which increasingly target patients in early biological stages of the disease.

The platform's use of circular RNA as a biomarker class, rather than the amyloid or tau proteins that underpin most existing Alzheimer's blood tests, represents a distinct technical approach within the field.

What Comes Next

Circular Genomics has not announced a timeline for regulatory submission or disclosed commercial distribution agreements, and the company is expected to provide additional details on the platform's clinical availability and regulatory pathway in subsequent communications.